Theorem Clinical Research

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Qiagen, Tokai Pharmaceuticals partner

Wednesday, March 18, 2015 01:18 PM

Qiagen, a Netherlands-based holding company, has partnered with Germany-based Tokai Pharmaceuticals to combine new circulating tumor cells (CTCs) technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies demonstrated potential utility to guide therapy choice in CRPC patients.

More... »

Quest Diagnostics

CRF Health launches eCOA solution for global diabetes trials

Wednesday, March 18, 2015 01:17 PM

CRF Health, a global provider of eCOA solutions for the life sciences industry headquartered in Plymouth Meeting, Pa., has launched a complete TrialMax eCOA solution for diabetes clinical trials. Developed with clinicians and patients to optimize usability and compliance, the solution enables investigators to collect patient reported outcome assessments and deliver defensible data, while minimizing patient and site burden. Already being used in four major global diabetes trials, covering 700 investigative sites and 3,250 patients, the solution offers complete integration between patient eDiary entry and blood glucose measurements.

More... »


NantWorks, Sorrento collaborate on novel anti-cancer immunotherapies

Wednesday, March 18, 2015 01:16 PM

NantWorks, an umbrella organization developing of next generation diagnostics and therapeutics, and Sorrento Therapeutics, an oncology company, have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

More... »

Kite Pharma acquires T-Cell Factory for $21M

Wednesday, March 18, 2015 01:14 PM

Kite Pharma, a Santa Monica, Calif.-based, clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on CAR and TCR gene therapy platforms for the treatment of cancer, acquired T-Cell Factory (TCF), a privately held Dutch company, which has been renamed Kite Pharma E.U.

More... »

$100M invested in new Dementia Discovery fund

Wednesday, March 18, 2015 01:11 PM

The U.K. government has announced over $100 million will be invested in a pioneering new global Dementia Discovery Fund. Major pharmaceutical companies Biogen Idec, GlaxoSmithKline, Johnson & JohnsonEli Lilly and Pfizer have all committed in principle to investing in the project, alongside Alzheimer's Research U.K. and the U.K. government.

More... »

Cloud Pharmaceuticals, University of Florida collaborate

Wednesday, March 18, 2015 01:09 PM

Cloud Pharmaceuticals, a Research Triangle Park, N.C.-based therapeutics company focused on cloud-based drug design and development, and the University of Florida’s department of medicine have announced an academic collaboration to help rapidly design and develop novel drugs to inhibit the reproduction of cancer cells.

More... »

Study: How much should cancer drugs cost?

Monday, March 16, 2015 01:54 PM

The true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered, according to a Cornell University researchers based on a study, A Quality-Adjusted Price Index for Colorectal Cancer Drugs, released by the National Bureau of Economic Research (NBER).

More... »

Report: Clinical trial sponsors fail to report results to participants, public

Monday, March 16, 2015 01:52 PM

Despite legal and ethical mandates for disclosure, results from most clinical trials of medical products are not reported promptly on a registry specifically created to make results of human studies publicly available, according to Duke Medicine researchers.

More... »

New immunotechnology center MI-mAbs launched

Monday, March 16, 2015 01:48 PM

MI-mAbs, a new immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease and founding member of the France-based Marseille Immunopole (MI) cluster, has announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Universite (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC); three of their research centers (the Centre d'Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Center for Immunophenomics); Innate Pharma, a European immuno-oncology company; and Sanofi.

More... »

Second Genome, Evotec to collaborate in microbiome discovery and development

Monday, March 16, 2015 01:47 PM

Evotec, a drug discovery alliance and development partnership company based in Germany, and Second Genome, a South San Francisco-based therapeutic developer, are collaborating on small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

More... »

AiCure
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs